Nanology.us – Advancing Tumor-Directed Drug Therapy
  • About
    • Overview
    • Team & Advisors
    • Partnering Opportunities
  • Technology
  • Development
    • Products
    • Pipeline
    • Clinical Programs
    • Immunogenic Effect
    • Partnering Opportunities
  • News & Publications
  • Contact
    • Partnering Opportunities
    • Physicians and Patients
logo

Archive for the Publications Category

Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts

On December 15, 2022   /   Publications  
Back to Top

The Journal of Urology : Phase 1/2 Trial Results of a Large Surface Area Microparticle Docetaxel for the Treatment of High-Risk Nonmuscle-Invasive Bladder Cancer

On October 1, 2022   /   Publications  
Back to Top

Drug Delivery and Translational Research : Local Administration of Large Surface Area Microparticle Docetaxel to Solid Carcinomas Induces Direct Cytotoxicity and Immune-mediated Tumoricidal Effects: Preclinical and Clinical Studies

On September 6, 2022   /   Publications  
Back to Top

Respiratory Drug Delivery: Aggregated High Surface Area Particle Technology for Pulmonary Drug Delivery

On July 27, 2022   /   Publications  
Back to Top

Endoscopic Ultrasound: An Update on EUS-Guided Ablative Techniques for Pancreatic Cyctic Lesions

On May 12, 2022   /   Publications  
Back to Top

Breast Cancer Research & Treatment: Phase 1/2 Study of Topical Submicron Particle Paclitaxel for Cutaneous Metastases of Breast Cancer

On April 26, 2022   /   Publications  
Back to Top

Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions

On August 24, 2021   /   Home Page, Publications  
Medical Oncology: Submicron particle docetaxel intratumoral injection in combination with anti-mCTLA-4 into 4T1-Luc orthotopic implants reduces primary tumor and metastatic pulmonary lesions
Back to Top

Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies

On November 10, 2020   /   Home Page, Publications  
Drug Delivery and Translational Research: Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies
Back to Top

Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery

On September 17, 2020   /   Home Page, Publications  
Gynecologic Oncology Reports: Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery

Phase II study of intraperitoneal submicron particle paclitaxel (SPP) plus IV carboplatin and paclitaxel in patients with epithelial ovarian cancer surgery

Back to Top

Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood

On April 3, 2020   /   Home Page, Publications  
Investigational New Drugs: Intratumoral Submicron Particle Docetaxel Inhibits Syngeneic Renca Renal Cancer Growth & Increases CD4+, CD8+ and Treg Levels in Peripheral Blood

Investigational New Drugs: Intratumoral submicron particle docetaxel inhibits syngeneic Renca renal cancer growth and increases CD4+, CD8+, and Treg levels in peripheral blood

Back to Top

Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer

On August 1, 2019   /   Home Page, Publications  
Journal of Aerosol Medicine and Pulmonary Drug Delivery: Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer

Inhaled Submicron Particle Paclitaxel (NanoPac®) Induces Tumor Regression and Immune Cell Infiltration in an Orthotopic Athymic Nude Rat Model of Non-Small Cell Lung Cancer

Back to Top

Cancers 2019: Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

On May 3, 2019   /   Publications  

Local Injection of Submicron Particle Docetaxel is Associated with Tumor Eradication, Reduced Systemic Toxicity and an Immunologic Response in Uro-Oncologic Xenografts

Back to Top

Journal of Aerosol Medicine and Pulmonary Drug Delivery: Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model

On October 29, 2018   /   Publications  

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac®) in a Rodent Model

Back to Top

Cancer Chemotherapy & Pharmacology: Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies

On August 9, 2017   /   Publications  

Phase I study of intraperitoneal nanoparticulate paclitaxel (nanotax®) in patients with peritoneal malignancies

 

Back to Top

Recent Nanology News

  • NanOlogy General Presentation (January 2023) January 6, 2023
  • NanOlogy Publishes Results From a Clinical Trial of Intracystic LSAM-PTX in Mucinous Pancreatic Cysts December 20, 2022
  • Early phase trial of intracystic injection of large surface area microparticle paclitaxel for treatment of mucinous pancreatic cysts December 15, 2022
  • Jan 9-11 : Biotech Showcase, San Francisco December 7, 2022
  • Jan 9-13 : JP Morgan 41st Annual Healthcare Conference, San Francisco December 7, 2022

Home
About
Technology
Development
News & Publications
Contact

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.

© 2017-23 NanOlogy LLC     Legal
Back to Top
This website uses cookies to improve your experience. By clicking "Accept", you consent to the use of ALL the cookies. However you may visit the Cookie Settings to provide a controlled consent. Cookie settings ACCEPT
Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled

This is an necessary category.

Non Necessary

This is an non-necessary category.

Save & Accept